IOL Chemicals and Pharmaceuticals share news and announcements
NSE: IOLCPBSE: 524164Pharmaceuticals & BiotechnologySmall Cap
Last close ₹164.14down ₹7.22 (4.21%)BSE ₹163.40
Share price at the NSE close on 23 Oct 2026. Previous close ₹171.36.
52-week range of traded prices to 23 Oct 2026
₹67.19Low, 16 Mar 2026₹224.00High, 7 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 30 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹4,818 Cr1,024th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 28.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 20 May 2026
- 2.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.61%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 9.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 20 May 2026
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 31,10,55637.2% delivered
IOL Chemicals and Pharmaceuticals board meetings
123 filed, newest first. Page 2 of 3.
Nov 2019
Aug 2019
12 Aug · Board meeting
Jul 2019
May 2019
29 May · Board meeting
Feb 2019
12 Feb · Board meeting
Nov 2018
14 Nov · Board meeting
Aug 2018
11 Aug · Board meeting
Jul 2018
May 2018
16 May · Board meeting
Feb 2018
12 Feb · Board meeting
Nov 2017
Aug 2017
May 2017
Feb 2017
Jan 2017
Oct 2016
Aug 2016
Jul 2016
May 2016
Apr 2016
Jan 2016
30 Jan · Board meeting
Oct 2015
23 Oct · Board meeting
Not held on this date
Aug 2015
May 2015
Feb 2015
5 Feb · Board meeting
Inter alia to consider and approve the un-audited financial results of the Company for the quarter ended December 31, 2014.
Dec 2014
1 Dec · Board meeting
Board of Directors in its meeting held on November 28, 2014 has considered and approved the following matters: 1. Un-audited financial results for the quarter/half year ended 30 September 2014 2. Allotment of 50,51,924 equity shares of face value of Rs 10/- each on conversion of US$ six million Zero Coupon Unsecured Foreign Currency Convertible Bonds issued in May 2010 to the bondholders and allotment of 8,41,987 equity shares of the face value Rs 10/- each on conversion of US $ one million bonds in the name of custodian on behalf of the bondholders, who have not submitted their conversion notices for mandatory conversion. The paid up capital of the company increased from 4,17,61,591 equity shares of Rs 10/- each to 4,76,55,502 equity shares of Rs 10/- each on the allotment aforesaid shares. 3. Constituted a Committee with M/s KPMG as its advisors, to unleash the potential of the company through the various options of joint ventures, restructuring of business etc.
Nov 2014
Oct 2014
29 Oct · Board meeting
27 Oct · Board meeting
Inter-alia to consider to exercise CALL OPTION by the company to convert FCCBs into equity shares.
Aug 2014
22 Aug · Board meeting
Board at its meeting held on August 22, 2014 approved the following: 1. The Board has approved the appointment of Dr Sandhya Mehta, as Additional and Independent Director w.e.f 22 August 2014. She has vast 22 experience to her credit. She has published seven books in addition to numerous papers published in reputed National & International Journals. She holds master degree in Business Management and Ph.D.14 Aug · Board meeting
1 Aug · Board meeting
Inter-alia to consider and approve the un-audited financial results of the Company for the quarter ended 30 June 2014.
Jul 2014
7 Jul · Board meeting
File name: “Outcome_of_Allotment_committee_04”
May 2014
30 May · Board meeting
Board of Directors in its meeting held on May 30, 2014 has considered and approved the following matters:(1) Constituted ESOP Compensation Committee to formulate, administer and supervise the Employee Stock Option Scheme.20 May · Board meeting
Inter alia to consider the preferential issue of shares/ warrants to the promoters and non-promoters of the Company.